PT  - JOURNAL ARTICLE
AU  - Kemp, Merlisa
AU  - Johannes, Clint
AU  - van Rensburg, Susan J
AU  - Kidd, Martin
AU  - Isaacs, Ferial
AU  - Kotze, Maritha J
AU  - Engel-Hills, Penelope
TI  - Disability in Multiple Sclerosis is Associated with Vascular Factors: An Ultrasound study
AID  - 10.1101/2022.09.11.22279820
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.11.22279820
4099  - http://medrxiv.org/content/early/2022/09/12/2022.09.11.22279820.short
4100  - http://medrxiv.org/content/early/2022/09/12/2022.09.11.22279820.full
AB  - Background Although multiple sclerosis (MS) is an immune-related disorder, pharmaceutical interventions targeting the immune system do not stop or reverse disability progression; the major challenge for this condition. Studies show that disability progression in MS is associated with vascular comorbidity and brain volume loss, indicating that a multi-targeted approach is required to prevent debilitation. The aim of the present study was to examine the associations between vascular ultrasound, disability, biochemistry and lifestyle data in people with MS (pwMS).Methods Extracranial vascular ultrasound was performed on 51 pwMS and 25 age-matched controls. Sonographic interrogation determined carotid intima-media thickness (cIMT) and abnormal blood flow patterns. Disability was assessed using the Expanded Disability Status Scale (EDSS). Biochemical and lifestyle data were obtained for all participants.Results The EDSS had a highly significant positive association with the cIMT of the right (r = 0.63; p = 0.001) and left (r = 0.49; p = 0.001) common carotid arteries and negative associations with the peak systolic blood flow velocity of the right vertebral artery (r = -0.42; p = 0.01) as well as end-diastolic velocity of the left internal carotid artery (r = -0.47; p = 0.01). These associations were significantly influenced by biochemical and lifestyle factors. Both cIMT and age showed significant associations with the EDSS. When cIMT was adjusted for age in a regression analysis, the association between the EDSS and the cIMT remained significant (p < 0.01), while the age association was reduced to being significant only at 10% (p = 0.06). There was no association between the use of MS medication and the EDSS (p = 0.56).Conclusion PwMS who had increased cIMT, a surrogate marker for atherosclerosis, and reduced carotid artery blood flow velocities were at risk for greater disability over and above the effect of aging. These findings provide important information for disease management and disability prevention in pwMS. Modification of diet and lifestyle may promote the unhindered flow of essential nutritional factors into the brain in pwMS.Competing Interest StatementMaritha J Kotze: Director and shareholder of Gknowmix (Pty) Ltd., a spin out company of the South African Medical Research Council. Susan J van Rensburg: Scientific Advisor of Gknowmix (Pty) Ltd., which provided the platform for research translation relevant to this project. The remaining authors declared no conflict of interest. Funding StatementThe study was funded by the National Research Foundation and the Cape Peninsula University of Technology, Cape Town, South AfricaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Faculty of Health and Wellness Sciences Research Ethics Committee (FREC) (Reference no: CPUT/HW-REC 2017/H4) and the Human Research Ethics Committee (HREC) of the University of Stellenbosch (Reference no: N07/09/203).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors